U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H12N2O4
Molecular Weight 224.2137
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of STAVUDINE

SMILES

Cc1cn([C@@]2([H])C=C[C@@]([H])(CO)O2)c(=O)nc1O

InChI

InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N
InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H12N2O4
Molecular Weight 224.2137
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf

Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.

Originator

Curator's Comment:: # Bristol-Myers Squibb; Yale University; Yamasa Corporation

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zerit

Approved Use

ZERIT (stavudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection

Launch Date

772329600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
228 ng/mL
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
STAVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
536 ng/mL
40 mg 2 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
STAVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1966 ng × h/mL
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
STAVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2568 ng × h/mL
40 mg 2 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
STAVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
STAVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
100%
40 mg 2 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
STAVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Other AEs: Abdominal pain, Asthenia...
Other AEs:
Abdominal pain (19%)
Asthenia (18%)
Headache (25%)
Diarrhea (34%)
Dyspepsia (12%)
Nausea (24%)
Vomiting (12%)
Lipodystrophy (6%)
Arthralgia (6%)
Myalgia (4%)
Abnormal dreams (19%)
Depressive disorders (13%)
Dizziness (26%)
Insomnia (22%)
Neuropathy (13%)
Paresthesia (12%)
Cough increased (9%)
Rhinitis (11%)
Rash (35%)
Skin discoloration (<1%)
Sources:
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (43 patients)
Diarrhea (34 patients)
Headache (25 patients)
Rash (18 patients)
Vomiting (18 patients)
Neuropathy peripheral (8 patients)
Sources:
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (53 patients)
Diarrhea (45 patients)
Headache (46 patients)
Rash (30 patients)
Vomiting (30 patients)
Neuropathy peripheral (21 patient)
Sources:
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Headache, Diarrhea...
Other AEs:
Headache (54 patients)
Diarrhea (50 patients)
Neuropathy peripheral (52 patients)
Rash (40 patients)
Nausea and vomiting (39 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Rhinitis 11%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Dyspepsia 12%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Paresthesia 12%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Vomiting 12%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Depressive disorders 13%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Neuropathy 13%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Asthenia 18%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Abdominal pain 19%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Abnormal dreams 19%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Insomnia 22%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Nausea 24%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Headache 25%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Dizziness 26%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Diarrhea 34%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Rash 35%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Myalgia 4%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Arthralgia 6%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Lipodystrophy 6%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Cough increased 9%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Skin discoloration <1%
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 36.5
Health Status: unhealthy
Age Group: 36.5
Sex: M+F
Sources:
Rash 18 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Vomiting 18 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Headache 25 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea 34 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Nausea 43 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Neuropathy peripheral 8 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Neuropathy peripheral 21 patient
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Rash 30 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Vomiting 30 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea 45 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Headache 46 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Nausea 53 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Nausea and vomiting 39 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Rash 40 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea 50 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Neuropathy peripheral 52 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Headache 54 patients
40 mg 2 times / day multiple, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
unlikely
weak
weak
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line.
1998
Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis.
1999 Jan
[Conjugates of 2',3'-didehydro-3'-deoxythymidine with thymogen. Synthesis and anti-HIV activity].
1999 Jul
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
1999 Mar
Didanosine-induced hepatitis.
2000 Aug
Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
2000 Feb 18
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.
2000 Jan 28
Synthesis and antiviral activity of C-5 substituted analogues of d4T bearing methylamino- or methyldiamino-linker arms.
2000 May-Jun
Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report.
2000 Sep
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
2000 Sep 18
Macrocytosis in patients on stavudine.
2001
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1.
2001 Apr
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
2001 Apr 13
R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.
2001 Apr 15
The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.
2001 Apr 27
Antiviral drugs: current state of the art.
2001 Aug
Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.
2001 Aug 1
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
2001 Aug 15
Bristol-Myers warns of AIDS drugs' use.
2001 Feb
Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy.
2001 Feb 16
Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.
2001 Jan
Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.
2001 Jan 1
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
2001 Jan 5
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.
2001 Jan-Feb
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
Predictors of protease inhibitor-associated adverse events.
2001 Jul
Gynaecomastia in a male patient during stavudine and didanosine treatment for HIV infection.
2001 Jul
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.
2001 Jul-Aug
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.
2001 Jun 29
Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.
2001 May 25
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
2001 Sep
Patents

Sample Use Guides

Adults: The recommended dose based on body weight is as follows:
Route of Administration: Oral
The concentration of Stavudine necessary to inhibit HIV-1 replication by 50% (EC50) ranged from 0.009 to 4 uM
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:06 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:06 UTC 2021
Record UNII
BO9LE4QFZF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
STAVUDINE
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
STAVUDINE [WHO-IP]
Common Name English
STAVUDINE [MI]
Common Name English
STAVUDINE [USAN]
Common Name English
STAVUDINE (D4T) [VANDF]
Common Name English
ZERIT
Brand Name English
D-4T
Code English
STAVUDINE [USP MONOGRAPH]
Common Name English
NSC-163661
Code English
STAVUDINE [INN]
Common Name English
STAVUDINE [EP MONOGRAPH]
Common Name English
STAVUDINE [WHO-DD]
Common Name English
SANILVUDINE
JAN  
Common Name English
THYMIDINE, 2',3'-DIDEHYDRO-3'-DEOXY-
Systematic Name English
NSC-759897
Code English
STAVUDINUM [WHO-IP LATIN]
Common Name English
STAVUDINE [EMA EPAR]
Common Name English
STAVUDINE [HSDB]
Common Name English
STAVUDINE [EP]
Common Name English
ZIDOVUDINE IMPURITY A [WHO-IP]
Common Name English
1-((2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE
Common Name English
STAVUDINE (DT4) [VANDF]
Common Name English
STAVUDINE [ORANGE BOOK]
Common Name English
ZIDOVUDINE IMPURITY A [EP]
Common Name English
STAVUDINE [MART.]
Common Name English
1-(2,3-DIDEOXY-.BETA.-D-GLYCERO-PENT-2-ENOFURANOSYL)THYMINE
Common Name English
STAVUDINE [USP-RS]
Common Name English
SANILVUDINE [JAN]
Common Name English
D4T
Code English
Classification Tree Code System Code
NDF-RT N0000175462
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
NDF-RT N0000009947
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/STA)
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
NCI_THESAURUS C97452
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
WHO-VATC QJ05AF04
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
EMA ASSESSMENT REPORTS ZERIT (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
WHO-VATC QJ05AR07
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
LIVERTOX 899
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
WHO-ATC J05AR07
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
WHO-ATC J05AF04
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C1428
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
RXCUI
59763
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
STAVUDINE
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
INN
6775
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
STAVUDINE
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY Description: A white to almost white powder. Solubility: Soluble in water and sparingly soluble in ethanol (~750 g/l) TS. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Stavudine should be kept in a well-closed container, protected from light. Additional information: Stavudine may exhibit polymorphism. Definition: Stavudine contains not less than 97.0% and not more than 103.0% of C10H12N2O4, calculated with reference to the dried substance.
USP_CATALOG
1620209
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY USP-RS
DRUG CENTRAL
2478
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
CAS
3056-17-5
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
FDA UNII
BO9LE4QFZF
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
LACTMED
Stavudine
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
MESH
D018119
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
EPA CompTox
3056-17-5
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
PUBCHEM
18283
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
DRUG BANK
DB00649
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
EVMPD
SUB10642MIG
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
ChEMBL
CHEMBL991
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
MERCK INDEX
M10199
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY Merck Index
HSDB
7338
Created by admin on Fri Jun 25 21:02:07 UTC 2021 , Edited by admin on Fri Jun 25 21:02:07 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
Related Record Type Details
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
MINOR
URINE
Related Record Type Details
IMPURITY -> PARENT
Water (2.5.12): maximum 0.5 per cent, determined on 0.500 g.
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION